Yıl: 2021 Cilt: 27 Sayı: 3 Sayfa Aralığı: 219 - 228 Metin Dili: Türkçe DOI: 10.4274/tnd.2021.45649 İndeks Tarihi: 14-01-2022

İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış

Öz:
Sıklıkla doğurganlık çağındaki obez kadınlarda görülen, “psödotümör serebri” ya da diğer adıyla “idyopatik intrakraniyal hipertansiyon (İİH)” tanımlanabilir nedensel faktörler olmaksızın görülen intrakraniyal basınç artışıdır. Hem kalıcı görme kaybı hem de sanılandan yüksek nüks riski nedeniyle İİH’li hastalar multidispliner bir yaklaşımla, uzun süre yakından takip edilmelidir. Her hasta için yapılacak bireye özgü planlama ile baş ağrısı ve papilödemin şiddeti, görme kaybının varlığı, tıbbi tedaviye alınan yanıt ve komorbid durumlar göz önünde bulundurularak İİH tedavisi düzenlenmelidir. Kilo verme ve asetozolamid ile yeterli fayda görülemediği durumlarda hızla diğer medikal ve izleyen dönemde cerrahi tedavi seçenekleri değerlendirilmelidir. İİH’nin patogenezi tam olarak bilinmediği için, farklı teorileri destekleyen tedavi seçenekleri mevcuttur. Yeni gelişen ve klinik deneyimin son yıllarda arttığı farklı tedaviler ile hastalarda kalıcı komplikasyonların gelişme riskinin önüne geçilmeye çalışılmaktadır. Bu derlemenin amacı İİH tedavisindeki seçeneklerin güncel yaklaşımlar ile değerlendirilmesi ve klinisyene karar verme sürecinde yardımcı olabilmesidir.
Anahtar Kelime:

Current Overview of Idiopathic Intracranial Hypertension

Öz:
Pseudotumor cerebri, also known as idiopathic intracranial hypertension (IIH), is an increment in the intracranial pressure without identifiable causal factors. The disorder is frequently seen in obese women of childbearing age. Due to both permanent vision loss and higher risk of recurrence than previously thought, patients with IIH should be followed closely using a multidisciplinary approach. IIH treatment should be arranged considering the severity of headache and papilledema, presence of vision loss, response to medical treatment, and comorbid conditions, with individual planning for each patient. In patients where weight loss and acetazolamide are insufficient for symptoms’ resolution, other medical and surgical treatment options should be evaluated rapidly. Because the pathogenesis of IIH is not fully known, treatment options support different theories. With the increase in clinical experience, the aim is to prevent the risk of developing irreversible complications in patients using different treatments, which have recently been developed. This review aimed to evaluate IIH treatment options using current approaches and help physicians in the decision-making process.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013;81:1159-1165.
  • 2. Yunisova G, Güngör I, Kocasoy Orhan E, Baykan B. Stabbing headache as the presenting symptom of idiopathic intracranial hypertension. Headache 2017;57:1152-1153.
  • 3. Mollan SP, Ali F, Hassan-Smith G, et al. Evolving evidence in adult idiopathic intracranial hypertension: Pathophysiology and management. J Neurol Neurosurg Psychiatry 2016;87:982-992.
  • 4. Ekizoglu E, Baykan B, Orhan EK, Ertas M. The analysis of allodynia in patients with idiopathic intracranial hypertension. Cephalalgia 2012;32:1049-1058.
  • 5. Toscano S, Lo Fermo S, Reggio E, et al. An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. J Neurol 2021;268:3249-3268.
  • 6. Boddu S, Dinkin M, Suurna M, et al. Resolution of pulsatile tinnitus after venous sinus stenting in patients with Idiopathic Intracranial Hypertension. PLoS One 2016;11:e0164466.
  • 7. Wall M, Kupersmith MJ, Kieburtz KD, et al. The idiopathic intracranial hypertension treatment trial clinical profile at baseline. JAMA Neurol 2014;71:693-701.
  • 8. Bidot S, Bruce BB, Saindane AM, Newman NJ, Biousse V. Asymmetric papilledema in idiopathic intracranial hypertension. J Neuroophthalmol 2015;35:31-36.
  • 9. Wall M, Falardeau J, Fletcher WA, et al. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurol 2015;85:799- 805.
  • 10. Thurtell MJ. Idiopathic intracranial hypertension. Continuum (Minneap Minn) 2019;25:1289-1309.
  • 11. Tata G, Kisabay A, Gokcay F, Celebisoy N. Idiopathic intracranial hypertension: Are there predictors for visual outcome or recurrences? Clin Neurol Neurosurg 2019;183:105378.
  • 12. Hilely A, Hecht I, Goldenberg-Cohen N, Leiba H. Long-term follow-up of pseudotumor cerebri syndrome in prepubertal children, adolescents, and adults. Pediatr Neurol 2019;101:57-63.
  • 13. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-781.
  • 14. Chen J, Wall M. Epidemiology and risk factors for idiopathic intracranial hypertension. Int Ophthalmol Clin 2014;54:1-11.
  • 15. Mallery RM, Rehmani OF, Woo JH, et al. Utility of magnetic resonance imaging features for improving the diagnosis of idiopathic intracranial hypertension without papilledema. J Neuroophthalmol 2019;39:299-307.
  • 16. Bono F, Cristiano D, Mastrandrea C, et al. The upper limit of normal CSF opening pressure is related to bilateral transverse sinus stenosis in headache sufferers. Cephalalgia 2010;30:145-151.
  • 17. Baykan B, Ekizoğlu E, Altiokka G. An update on the pathophysiology of idiopathic intracranial hypertension alias pseudotumor cerebri. Agri 2015;27:63-72.
  • 18. Zierle-Ghosh A, Jan A. Physiology, Body Mass Index. 2021 Jul 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
  • 19. Mollan SP, Ali F, Hassan-Smith G, et al. Evolving evidence in adult idiopathic intracranial hypertension: Pathophysiology and management. J Neurol Neurosurg Psychiatry 2016;87:982-992.
  • 20. Subramaniam S, Fletcher WA. Obesity and weight loss in idiopathic intracranial hypertension: a narrative review. J Neuroophthalmol 2017;37:197-205.
  • 21. Hornby C, Mollan SP, Botfield H, O’Reilly MW, Sinclair AJ. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol 2018;38:522-530.
  • 22. Berdahl JP, Fleischman D, Zaydlarova J, et al. Body mass index has a linear relationship with cerebrospinal fluid pressure. Invest Ophthalmol Vis Sci 2012;53:1422-1427.
  • 23. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010;341:c2701.
  • 24. Kesler A, Hadayer A, Goldhammer Y, Almog Y, Korczyn AD. Idiopathic intracranial hypertension: risk of recurrences. Neurology 2004;63:1737– 1739.
  • 25. Shah VA, Kardon RH, Lee AG, Corbett JJ, Wall M. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology 2008;70:634-640.
  • 26. Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011;76:1564–1567.
  • 27. Friedman DI. Contemporary management of the pseudotumor cerebri syndrome. Expert Rev Neurother 2019;19:881-893.
  • 28. Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The idiopathic intracranial hypertension treatment trial. J Am Med Assoc 2014;311:1641-1651.
  • 29. Ten Hove MW, Friedman DI, Patel AD, et al. Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol 2016;36:13-19.
  • 30. Falardeau J, Lobb BM, Golden S, Maxfield SD, Tanne E. The use of acetazolamide during pregnancy in intracranial hypertension patients. J Neuroophthalmol 2013;33:9-12.
  • 31. Çelebisoy N, Gökçay F, Şirin H, Akyürekli Ö. Treatment of idiopathic intracranial hypertension: Topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007;116:322-327.
  • 32. Dodick DW. Migraine. Lancet 2018;391:1315-1330.
  • 33. Thurtell MJ, Kawasaki A. Update in the management of idiopathic intracranial hypertension. Neurol Clin 2021;39:147-161.
  • 34. Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology 2007;68:229-232.
  • 35. Botfield HF, Uldall MS, Westgate CSJ, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med 2017;9:eaan0972.
  • 36. Markey KA, Uldall M, Botfield H, et al. Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases. J Pain Res 2016;9:223-232.
  • 37. Gathercole LL, Lavery GG, Morgan SA, et al. 11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev 2013;34:525-555.
  • 38. Markey K, Mitchell J, Botfield H, et al. 1b-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Commun 2020;2:fcz050.
  • 39. Rauz S, Cheung CMG, Wood PJ, et al. Inhibition of 11β-hydroxysteroid dehydrogenase type of 1 lowers intraocular pressure in patients with ocular hypertension. QJM 2003;96:481-490.
  • 40. Gilbert AL, Chwalisz B, Mallery R. Complications of optic nerve sheath fenestration as a treatment for idiopathic intracranial hypertension. Semin Ophthalmol 2018;33:36-41.
  • 41. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2014;32:363-396.
  • 42. Banta JT, Farris BK. Pseudotumor cerebri and optic nerve sheath decompression. Ophthalmology 2000;107:1907-1912.
  • 43. Killer HE, Jaggi GP, Flammer J, et al. Cerebrospinal fluid dynamics between the intracranial and the subarachnoid space of the optic nerve. Is it always bidirectional? Brain 2007;130:514–520.
  • 44. Bouffard MA. Fulminant idiopathic intracranial hypertension. Curr Neurol Neurosci Rep 2020;20:8.
  • 45. Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of csf diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. Am J Neuroradiol 2015;36:1899-1904.
  • 46. Owler BK, Besser M. Extradural hematoma causing venous sinus obstruction and pseudotumor cerebri syndrome. Child’s Nerv Syst 2005;21:262-264.
  • 47. Bussière M, Falero R, Nicolle D, et al. Unilateral transverse sinus stenting of patients with idiopathic intracranial hypertension. Am J Neuroradiol 2010;31:645-650.
  • 48. Kumpe DA, Bennett JL, Seinfeld J, et al. Dural sinus stent placement for idiopathic intracranial hypertension: clinical article. J Neurosurg 2012;116:538-548.
  • 49. Elder BD, Rory Goodwin C, Kosztowski TA, et al. Venous sinus stenting is a valuable treatment for fulminant idiopathic intracranial hypertension. J Clin Neurosci 2015;22:685-689.
  • 50. Kanagalingam S, Subramanian PS. Cerebral venous sinus stenting for pseudotumor cerebri: a review Saudi J Ophthalmol 2015;29:3-8.
  • 51. Ahmed RM, Wilkinson M, Parker GD, et al. Transverse sinus stenting for idiopathic intracranial hypertension: A review of 52 patients and of model predictions. Am J Neuroradiol 2011;32:1408-1414.
  • 52. Starke RM, Wang T, Ding D, et al. Endovascular treatment of venous sinus stenosis in idiopathic intracranial hypertension: complications, neurological outcomes, and radiographic results. ScientificWorldJournal 2015;2015:140408.
  • 53. Kalyvas A, Neromyliotis E, Koutsarnakis C, et al. A systematic review of surgical treatments of idiopathic intracranial hypertension (IIH). Neurosurg Rev 2021;44:773-792.
  • 54. Giridharan N, Patel SK, Ojugbeli A, et al. Understanding the complex pathophysiology of idiopathic intracranial hypertension and the evolving role of venous sinus stenting: a comprehensive review of the literature. Neurosurg Focus 2018;45:E10.
  • 55. Lavoie P, Audet MÈ, Gariepy JL, et al. Severe cerebellar hemorrhage following transverse sinus stenting for idiopathic intracranial hypertension. Interv Neuroradiol 2018;24:100-105.
  • 56. Menger RP, Connor DE, Thakur JD, et al. A comparison of lumboperitoneal and ventriculoperitoneal shunting for idiopathic intracranial hypertension: an analysis of economic impact and complications using the nationwide inpatient sample. Neurosurg Focus 2014;37:E4.
  • 57. McGirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes J Neurosurg 2004;101:627-632.
  • 58. Kalyvas AV, Hughes M, Koutsarnakis C, et al. Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature. Acta Neurochir (Wien) 2017;159:33-49.
  • 59. Fraser JA, Bruce BB, Rucker J, et al. Risk factors for idiopathic intracranial hypertension in men: A case-control study. J Neurol Sci 2010;290:86-89.
  • 60. Breznikar B, Dinevski D. Bariatric surgery for morbid obesity: Pre-operative assessment, surgical techniques and post-operative monitoring. J Int Med Res 2009;37:1632-1645.
  • 61. Sun WYL, Switzer NJ, Dang JT, et al. Idiopathic intracranial hypertension and bariatric surgery: A systematic review. Can J Surg 2020;63:E123-E128.
  • 62. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev 2014:CD003641.
  • 63. Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 2018;89:1088-1100.
  • 64. Merola J, Selezneva L, Perkins R, et al. Cerebrospinal fluid diversion versus bariatric surgery in the management of idiopathic intracranial hypertension. Br J Neurosurg 2020;34:9-12.
  • 65. De Simone R, Marano E, Fiorillo C, et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005;25:342-344.
  • 66. Gates P, McNeill P. A possible role for temporary lumbar drainage in the management of idiopathic intracranial hypertension. Neuroophthalmol 2016;40:277-280.
  • 67. Bir LS, Degirmenci E, Erdogan C, Bilgin S, Coşkun E. Rapid recovery of visual acuity after lumboperitoneal shunt operation in malignant idiopathic intracranial hypertension. Case Rep Ophthalmol Med 2011;2011:405838.
  • 68. Governale LS, Fein N, Logsdon J, Black PM. Techniques and complications of external lumbar drainage for normal pressure hydrocephalus. Neurosurgery 2008;63:378-384.
  • 69. Binz DD, Toussaint LG, Friedman JA. Hemorrhagic complications of ventriculostomy placement: a meta-analysis. Neurocrit Care 2009;10:253- 256.
APA Hasırcı Bayır B, Baykan B, Celebisoy N (2021). İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. , 219 - 228. 10.4274/tnd.2021.45649
Chicago Hasırcı Bayır Buse Rahime,Baykan Betul,Celebisoy Nese İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. (2021): 219 - 228. 10.4274/tnd.2021.45649
MLA Hasırcı Bayır Buse Rahime,Baykan Betul,Celebisoy Nese İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. , 2021, ss.219 - 228. 10.4274/tnd.2021.45649
AMA Hasırcı Bayır B,Baykan B,Celebisoy N İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. . 2021; 219 - 228. 10.4274/tnd.2021.45649
Vancouver Hasırcı Bayır B,Baykan B,Celebisoy N İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. . 2021; 219 - 228. 10.4274/tnd.2021.45649
IEEE Hasırcı Bayır B,Baykan B,Celebisoy N "İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış." , ss.219 - 228, 2021. 10.4274/tnd.2021.45649
ISNAD Hasırcı Bayır, Buse Rahime vd. "İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış". (2021), 219-228. https://doi.org/10.4274/tnd.2021.45649
APA Hasırcı Bayır B, Baykan B, Celebisoy N (2021). İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. Türk Nöroloji Dergisi, 27(3), 219 - 228. 10.4274/tnd.2021.45649
Chicago Hasırcı Bayır Buse Rahime,Baykan Betul,Celebisoy Nese İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. Türk Nöroloji Dergisi 27, no.3 (2021): 219 - 228. 10.4274/tnd.2021.45649
MLA Hasırcı Bayır Buse Rahime,Baykan Betul,Celebisoy Nese İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. Türk Nöroloji Dergisi, vol.27, no.3, 2021, ss.219 - 228. 10.4274/tnd.2021.45649
AMA Hasırcı Bayır B,Baykan B,Celebisoy N İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. Türk Nöroloji Dergisi. 2021; 27(3): 219 - 228. 10.4274/tnd.2021.45649
Vancouver Hasırcı Bayır B,Baykan B,Celebisoy N İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış. Türk Nöroloji Dergisi. 2021; 27(3): 219 - 228. 10.4274/tnd.2021.45649
IEEE Hasırcı Bayır B,Baykan B,Celebisoy N "İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış." Türk Nöroloji Dergisi, 27, ss.219 - 228, 2021. 10.4274/tnd.2021.45649
ISNAD Hasırcı Bayır, Buse Rahime vd. "İdyopatik İntrakraniyal Hipertansiyona Yaklaşımda Güncel Bakış". Türk Nöroloji Dergisi 27/3 (2021), 219-228. https://doi.org/10.4274/tnd.2021.45649